桂龙咳喘宁胶囊联合孟鲁司特钠片治疗支气管哮喘患者的效果  

Effects of Guilong Kechuanning capsules combined with Montelukast sodium tablets in treatment of bronchial asthma

作　　者：王帅 WANG Shuai(Department of Respiratory and Critical Care Medicine of Luohe Sixth People’s Hospital,Luohe 462000 Henan,China)

机构地区：[1]漯河市第六人民医院呼吸与危重症医学科,河南漯河462000

出　　处：《中国民康医学》2025年第6期103-106,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察桂龙咳喘宁胶囊联合孟鲁司特钠片治疗支气管哮喘患者的效果。方法:回顾性分析2021年6月至2023年6月该院收治的68例支气管哮喘患者的临床资料,按照治疗方法不同将其分为对照组和观察组各34例。对照组采用孟鲁司特钠片治疗,观察组在对照组基础上联合桂龙咳喘宁胶囊治疗。比较两组临床疗效,治疗前后中医证候积分(形寒肢冷、咳嗽气喘、痰液清稀、喉间哮鸣、鼻流清涕)、肺功能指标[呼气峰量流速(PEF)实测值/预计值、第1秒用力呼吸容积(FEV1)、用力肺活量(FVC)]水平、哮喘控制相关指标[呼出气一氧化氮(FeNO)、哮喘控制测试(ACT)]水平、血清生化指标[肿瘤坏死因子-α(TNF-α)、外周血嗜酸性粒细胞(EOS)计数、免疫球蛋白E(IgE)]水平,以及不良反应发生率。结果:观察组治疗总有效率为91.18%(31/34),高于对照组的70.59%(24/34),差异有统计学意义(P<0.05);治疗后,两组形寒肢冷、咳嗽气喘、痰液清稀、喉间哮鸣、鼻流清涕等中医证候积分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组PEF实测值/预计值、FEV1、FVC水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组FeNO水平均低于治疗前,且观察组低于对照组,两组ACT评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组TNF-α、EOS、IgE水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:桂龙咳喘宁胶囊联合孟鲁司特钠片治疗支气管哮喘患者可提高治疗总有效率和肺功能指标水平,改善哮喘控制相关指标水平,降低中医证候积分和血清生化指标水平,效果优于单纯孟鲁司特钠片治疗。Objective:To observe effects of Guilong Kechuanning capsules combined with Montelukast sodium tablets in treatment of patients with bronchial asthma.Methods:The clinical data of 68 patients with bronchial asthma admitted to this hospital from June 2021 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,34 cases in each group.The control group was treated with Montelukast sodium tablets,while the observation group was treated with Guilong Kechuanning capsules on the basis of that of the control group.The clinical efficacy,the TCM syndrome score(cold limbs,cough and asthma,clear and thin sputum,throat wheezing,nasal discharge),the levels of lung function indexes[peak expiratory flow(PEF)measured value/predicted value,forced expiratory volume in one second(FEV1),forced vital capacity(FVC)],asthma control related indexes[exhaled nitric oxide(FeNO),asthma control test(ACT)],and serum biochemical indexes[tumor necrosis factor-α(TNF-α),peripheral blood eosinophil(EOS)count,immunoglobulin E(IgE)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 91.18%(31/34),which was higher than 70.59%(24/34)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as cold limbs,cough and asthma,clear and thin sputum,throat wheezing and nasal discharge in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the PEF measured value/predicted value,FEV1 and FVC levels of the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FeNO levels of the t

关 键 词：支气管哮喘 桂龙咳喘宁胶囊 孟鲁司特钠 中医证候 肺功能 

分 类 号：R562.2[医药卫生—呼吸系统]